FDA: Don’t Use Cantrell Compounded Drug Products

Mar 02, 2018 - 11:59 AM

The Food and Drug Administration yesterday alerted health care professionals and patients not to use drug products produced by Cantrell Drug Co., including opioid products and other drugs intended for sterile injection, citing serious deficiencies in the company’s compounding operations. “Despite the FDA’s concerns about egregious conditions observed at Cantrell’s facility, during several inspections, with the most recent in 2017, the company continued to compound and distribute drugs without adequately addressing their potentially dangerous conditions,” said FDA Commissioner Scott Gottlieb, M.D. “This reckless activity threatens patient safety and will not be tolerated.” FDA has sought legal action to prevent the company from further producing and distributing drugs. It said health care professionals should immediately check their medical supplies, quarantine any drug products from the company and not administer them to patients. The agency is not aware of illness reports associated with the products, but asks health care professionals to report any associated adverse events or quality problems to its MedWatch program.

Related News Articles

Headline
FDA identifies recall of catheter kits, Early Alert for sterile labels
The Food and Drug Administration has identified a nationwide recall. Arrow International is recommending dialysis catheter kits containing Merit Medical 16F…
Headline
CMS, FDA announce pathway to expedite access to certain medical devices for Medicare beneficiaries
The Centers for Medicare & Medicaid Services and the Food and Drug Administration April 23 announced a new pathway to expedite access to certain FDA-…
Blog
Launching a National Effort to Improve Postpartum Hemorrhage Outcomes
h2, h3, h4 {color: #002855;} Postpartum hemorrhage (PPH) is one of the most common — and preventable — causes of maternal health in the United States. The…
Chairperson's File
Chair File: Leadership Dialogue — Innovation in Patient Safety with Amy Rockman of the AI Center of Excellence
Public
For decades, hospitals and health systems have used innovation to improve patient care and outcomes. We have seen dramatic improvements and know we can never…
Headline
AHA urges CMS to reduce burden on national provider identifier requirements for hospital off-campus PBDs
The AHA March 24 commented to the Centers for Medicare & Medicaid Services on upcoming requirements from the Consolidated Appropriations Act of 2026…
Headline
AHA celebrates Patient Safety Awareness Week 
March 8-14 marks Patient Safety Awareness Week. The AHA has several resources including podcasts, videos and reports that show how AHA members are advancing…